Expanding DAA Access Reduces HCV-Related Hospitalizations Among Patients With HIV, Study Finds

Infectious Disease Advisor (4/4, Nye) reported a study found that “although expanded access to direct-acting antivirals (DAAs) has reduced hepatitis C virus (HCV)-related hospitalizations among patients with HIV, further efforts are needed to address disparities in clinical outcomes for those with HCV and HIV coinfection.” Researchers observed that “for patients coinfected with HIV, the mean rate of HCV-related hospitalizations decreased significantly between the pre- and post-intervention period (from 24.6 to 15.6 per 10,000 patients).” They concluded, “Research is needed to develop community-informed models of care that remove structural and social barriers to access DAA treatment among people with HIV/HCV.” The study was published in Open Forum Infectious Diseases.